Taselisib (GDC-0032), a potent β-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations
Zachary S. Zumsteg, Natasha Morse, Gabriel Krigsfeld, Gaorav Gupta, Daniel S. Higginson, Nancy Y. Lee, Luc Morris, Ian Ganly, Stephan L. Shiao, Simon N. Powell, Christine H. Chung, Maurizio Scaltriti, José Baselga
Dive into the research topics of 'Taselisib (GDC-0032), a potent β-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations'. Together they form a unique fingerprint.